Navigation Links
Bradmer provides clinical trial update and announces evaluation of strategic alternatives
Date:2/17/2009

uradiab therapy is delivered directly into the surgical resection cavity in a separate procedure after the initial surgery. Neuradiab delivers a concentrated level of radiation specifically to the remaining cancer cells by targeting tenascin. Tenascin is a protein over-expressed in 99% of GBM cells but absent from normal brain cells.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, n
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
2. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
3. Bradmer announces 2008 third quarter operational and financial results
4. Bradmer to present at Rodman & Renshaw Healthcare Conference
5. Bradmer receives FDA approval to proceed with Phase III clinical trial
6. Bradmer announces 2008 first quarter operational and financial results
7. Bradmer announces new additions to management team
8. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
9. Notice of Bradmer Pharmaceuticals Conference Call
10. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
11. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Los Angeles, CA (PRWEB) July 29, 2014 ... on the website of Time Magazine titled “From Kim’s ... Want,” Kim Kardashian’s butt is the celebrity ... celebrities and their features include Beyoncé’s butt, Jennifer ... and lips. This information is based on data collected ...
(Date:7/29/2014)... (July 29, 2014) Using quality improvement measures in ... England Cardiovascular Disease Study Group, researchers have found a ... procedure with contrast dye. , Currently, 7-15 percent of ... contrast-dye end up with kidney injury, which can result ... to temporary or permanent dialysis, says a study published ...
(Date:7/29/2014)... Gainesville, FL (PRWEB) July 29, 2014 Many ... very first thing they do each morning is put on ... the bathroom. These same individuals also may be dissatisfied ... cataracts. , Cataracts may cause difficulty driving, especially ... harder to follow or find one’s golf ball, see the ...
(Date:7/29/2014)... New high priced hepatitis C drugs will increase ... $2.9 to $5.8 billion next year, according to a ... by the Pharmaceutical Care Management Association (PCMA). Milliman projects ... much as 8.6 percent in 2015 as a result ... , The study finds that the majority of new ...
(Date:7/29/2014)... Alan Mozes HealthDay ... Treating certain adult autism patients with just a single dose ... facial expressions and emotions, Japanese researchers report. Known as ... role in emotional bonding between lovers, and between mothers and ... activity in a key area of the brain that has ...
Breaking Medicine News(10 mins):Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Reducing kidney injury using a quality improvement method 2Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3
... , , KENILWORTH, N.J., Aug. 6 ... live Webcast of its Special Shareholders Meeting being held on Friday, ... between Schering-Plough and Merck & Co., Inc. Originating from Boston, ... corporate Web site, www.schering-plough.com . , , ...
... exposure associated with skin inflammation in study of myositis ... ultraviolet (UV) rays may trigger certain types of autoimmune ... "This study found that women who lived in areas ... an autoimmune muscle disease called myositis were more likely ...
... ... Health Letter focuses on the feet and their common ailments. Dr. James Ioli, chief of podiatry ... ... of our feet. They provide a steady base when we stand, serve as shock absorbers when ...
... Aug. 6 Vitamin Shoppe Industries Inc., a leading specialty ... will hold a conference call for its bondholders on Thursday, ... call, members of management will report on the Company,s second ... To participate in the teleconference, bondholders are invited to call ...
... BEIJING and BETHESDA, Md., Aug. 6 /PRNewswire-Asia/ -- ... ("Chindex") (Nasdaq: CHDX ), a leading,independent ... in,the People,s Republic of China, today announced that ... plans to,launch a comprehensive, international-standard oncology program, called ...
... , , SAN DIEGO, Aug. 6 AMN Healthcare Services, Inc. (NYSE: AHS ) today announced ... 2009 include: , , ... % Chg % Chg, ... Q2 2009 Q2 2008 Q1 2009, ------------------------------------------------------------, ...
Cached Medicine News:Health News:Sunlight May Cause Rash in Autoimmune Disease 2Health News:Harvard Health Letter Special Section Features the Body's Unsung Marvels: The Feet 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 4Health News:AMN Healthcare Announces Second Quarter 2009 Results 2Health News:AMN Healthcare Announces Second Quarter 2009 Results 3Health News:AMN Healthcare Announces Second Quarter 2009 Results 4Health News:AMN Healthcare Announces Second Quarter 2009 Results 5Health News:AMN Healthcare Announces Second Quarter 2009 Results 6Health News:AMN Healthcare Announces Second Quarter 2009 Results 7Health News:AMN Healthcare Announces Second Quarter 2009 Results 8Health News:AMN Healthcare Announces Second Quarter 2009 Results 9Health News:AMN Healthcare Announces Second Quarter 2009 Results 10Health News:AMN Healthcare Announces Second Quarter 2009 Results 11Health News:AMN Healthcare Announces Second Quarter 2009 Results 12Health News:AMN Healthcare Announces Second Quarter 2009 Results 13Health News:AMN Healthcare Announces Second Quarter 2009 Results 14Health News:AMN Healthcare Announces Second Quarter 2009 Results 15Health News:AMN Healthcare Announces Second Quarter 2009 Results 16
(Date:7/29/2014)... YORK , July 29, 2014  Longtime industry ... Caremark Rx, Drew Crawford today announced the ... the leading independent media source dedicated to delivering fair, ... on the pharmacy benefit management (PBM) industry .  ... of, and context behind, industry news.   The outlet will ...
(Date:7/29/2014)... , July 29, 2014 McGraw-Hill Education Professional, ... the science, technical, and medical communities, has announced the ... off-line mobile application of the world-renowned medical education platform. ... AccessMedicine App , available for download onto all ... be able to gain access to valuable AccessMedicine ...
(Date:7/29/2014)... According to a new market ... Devices Market - Global Forecast, Market Share, Size, Growth ... trauma fixation devices market is estimated at USD 6.1 ... a CAGR of 7.2% from 2014 to 2019, to ... 2020. Browse the Orthopedic Trauma Fixation Devices ...
Breaking Medicine Technology:Drew Crawford Announces Launch of PBM365 Media 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4
Blunt, fine curved shaft hook to unroll membranes. 24 gauge shaft with dark finish for reduced glare....
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
Angled 45 degrees, 10 mm shaft with 0.2 mm tip. Round knurled handle with dull finish. Overall length: 4.6 inches....
Straight 31 mm shaft with flat handle and polished finish. 0.5 mm cup. Overall length: 5 inches....
Medicine Products: